Four biotechs and a Matthew Roden-led SPAC price IPOs, raising a combined $528M
Four more biotechs and a SPAC led by Bristol Myers Squibb vet Matthew Roden have priced IPOs, closing out another busy week on Wall Street …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
